Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Macrogenics had a gross margin of N/A% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Macrogenics Gross Margin % Related Terms
Macrogenics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Macrogenics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M55 vs RNAC, CNXU, GALT: Gross Margin % Comparison
For the Biotechnology subindustry, Macrogenics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Macrogenics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Macrogenics (FRA:M55) has a Gross Margin % of 0.00% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Macrogenics and its competitors. Over the past decade, Macrogenics' Gross Margin % has ranged from 75.91 to 96.50. According to the industry distribution chart, Macrogenics ranks #196 out of 735 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Macrogenics' Gross Margin % too high?
Macrogenics' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 75.91 to a high of 96.50. Based on the distribution chart, Macrogenics ranks #196 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Macrogenics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Gross Margin % compare to RNAC and CNXU?
According to the Biotechnology industry distribution chart, Macrogenics ranks #196 out of 735 companies for Gross Margin %. This puts Macrogenics in the upper half of its industry. The industry median Gross Margin % is 60.96. Historically, Macrogenics' own Gross Margin % has ranged from 75.91 to 96.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.96, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Macrogenics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Macrogenics (FRA:M55) has a current Gross Margin % of 0.00%. The stock's GF Value™ is €3.33, compared to a current price of €3.42 — trading 2.7% above its estimated fair value. The current Gross Margin % is 0.00%. Macrogenics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Gross Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of €3.42 is trading 2.7% above its estimated GF Value™ of €3.33.
Key valuation signals for FRA:M55:
Gross Margin %: 0.00%
GF Value™: €3.33 vs. price of €3.42 (2.7% above fair value)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
51GF Score
Get the complete analysis for FRA:M55
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 
